Bone & Joint Research Institute, Zhongshan Hospital, Xiamen University, Xiamen, 361102, China.
School of Medicine, Xiamen University, Xiamen, 361102, China.
Eur J Med Res. 2023 Sep 9;28(1):332. doi: 10.1186/s40001-023-01267-4.
Although the chondroprotection of peroxisome proliferator-activated receptor α (PPARα) activation against osteoarthritis (OA) has been revealed, the regulatory mechanism of PPARα deficiency to aggravate osteoarthritic cartilage deterioration remains unclear. Here, we aimed to investigate whether and how autophagy is involved in OA pathological progression.
Model of experimental OA was established using destabilization of the medial meniscus in PPARα-KO 129S4/SvJae male mice, followed by histopathological detection of articular cartilage and immunohistochemistry detection of extracellular matrix (ECM) or autophagy-related signal molecules. Meanwhile, human OA chondrocytes obtained from total knee replacement surgery patients with OA were cultured with the pretreatment of IL-1β, followed with the treatment of PPARα agonist WY14643 and the detection of related signal molecules.
PPARα deficiency aggravated cartilage damage with decreased LC3B level in combination with an increase in P62 level, accompanied with reduced p-Akt and p-ERK levels in PPARα-KO mouse model of experimental OA. On the contrary, PPARα activation by WY14643 promoted ECM synthesis in IL-1β-treated human OA chondrocytes, accompanied with increased LC3B-II/I ratio and Beclin 1 level and decreased P62 and Bcl2 levels. Meanwhile, it was observed that activated ERK and Akt by PPARα activation contributed to the enhancement of autophagy and ECM synthesis in human OA chondrocytes.
Impaired autophagy contributed to the aggravated deterioration of osteoarthritis articular cartilage by PPARα deficiency associated with the suppression of ERK and Akt, with an implication that triggering PPARα activation ought to be a potential promising therapeutic target for OA therapy.
尽管过氧化物酶体增殖物激活受体 α(PPARα)的激活具有软骨保护作用,可对抗骨关节炎(OA),但其缺乏加剧 OA 软骨退变的调节机制仍不清楚。在此,我们旨在研究自噬是否以及如何参与 OA 病理进展。
使用 129S4/SvJae 雄性小鼠内侧半月板不稳定建立实验性 OA 模型,随后进行关节软骨组织学检测和细胞外基质(ECM)或自噬相关信号分子的免疫组织化学检测。同时,培养来自 OA 全膝关节置换术患者的 OA 人软骨细胞,用 IL-1β 预处理,然后用 PPARα 激动剂 WY14643 处理,检测相关信号分子。
PPARα 缺乏加重了软骨损伤,LC3B 水平降低,同时 P62 水平升高,与实验性 OA 小鼠模型中 PPARα-KO 的 p-Akt 和 p-ERK 水平降低有关。相反,WY14643 激活 PPARα 促进了 IL-1β 处理的人 OA 软骨细胞中 ECM 的合成,同时 LC3B-II/I 比值和 Beclin 1 水平增加,P62 和 Bcl2 水平降低。同时,观察到 PPARα 激活激活的 ERK 和 Akt 有助于增强人 OA 软骨细胞中的自噬和 ECM 合成。
PPARα 缺乏导致自噬受损,从而加剧 OA 关节软骨的退变,与 ERK 和 Akt 的抑制有关,提示激活 PPARα 可能是 OA 治疗的潜在有希望的治疗靶点。